Pacific Biosciences of California PACB Available-for-Sale Debt Securities - Fair Value by Maturity

Available-for-Sale Debt Securities - Fair Value by Maturity at other companies

AzentaAZTA

——

Revenue$37.2M+0.1%

Gross profit$12.8M+1,037%

Operating income-$8.4M+98.1%

Net income-$8.3M+98.1%

EPS (diluted)-$0.03+97.9%

Cash & equivalents$57.9M-4.7%

Total debt$59.3M+12.1%

Total equity$2.4M-97.4%

Total assets$782.4M-9.1%

Operating cash flow-$44.7M-1.4%

CapEx$3.0M+119%

Free cash flow-$47.7M-5.0%

Market cap$496.96M+30.4%

Enterprise value$498.38M+33.5%

P/S3.1×+0.6×

Gross margin37.5%+21.3pp

Operating margin-83.3%-38.2pp

Net margin-80.3%-36.1pp

FCF margin-72.6%-20.0pp

Return on equity-273.6%+314pp

Debt / equity25.1×+24.5×

Current ratio5.7×-1.0×

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate.

The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Pacific Biosciences of California's available-for-sale debt securities - fair value by maturity?: Pacific Biosciences of California (PACB) reported available-for-sale debt securities - fair value by maturity of $219.69M in Q1 2026.
How has Pacific Biosciences of California's available-for-sale debt securities - fair value by maturity changed year-over-year?: Pacific Biosciences of California's available-for-sale debt securities - fair value by maturity decreased by 26.8% year-over-year, from $300.16M to $219.69M.